Pharmacokinetics of ZSP1273 in Elder Participants

Inclusion criteria

• Signature of a dated Informed Consent Form (ICF) indicating that the participates has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
• Participants must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
• Body weight is no less than 50 kg in males and no less than 45 kg in females. Body mass index (BMI) 18≤BMI<28 kg/m2,BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
• Heart rate between 50-100 beats/min, Body temperature between 35.7-37.5℃

Young Participants Only:

• Participants must be ≥18 to ≤45 years old

Elder Participants Only:

• Participants must be ≥65 years old

Exclusion criteria

• Participants with an allergic disposition (multiple drug and food allergies)
• Participants who donated blood or bleeding profusely (> 400 mL) in the 3 months.
• Participants with clinically significant disease, such as gastrointestinal disease, infection (e.g., respiratory or central nervous system infection), within 2 weeks before screening;
• Participants who could not tolerate blood collection by venipuncture and/or had a history of dizzy with blood and needles

Young Participants Only:

• Participants had taken or planned to take any prescription medication, over-the-counter medication, vitamin product, or herbal medicine within 2 weeks before screening;
• Physical examination, vital signs, laboratory tests (blood routine +CRP, urine routine + urine sediment, blood biochemistry, coagulation function, infectious disease test, glycosylated hemoglobin test), 12-lead electrocardiogram, chest CT, abdominal color Doppler ultrasound and other examinations have clinical significance

Elder Participants Only:

• Participants had a history of or evidence of cardiovascular disease before screening: uncontrolled hypertension, orthostatic hypotension, severe arrhythmia, heart failure, Adams-stokes syndrome, unstable angina, myocardial infarction within the past 6 months before screening, or history of tachycardia/bradycardia requiring medical treatment, and degree II-III atrioventricular block.
• Participants who had other serious organ-systemic serious diseases at screening, including but not limited to respiratory, neurologic, hematologic, endocrine, oncologic, immunologic, psychiatric, or cardio-cerebrovascular diseases, and was judged by the investigator to be ineligible for participation in the trial